STAAR Shareholders Gear Up to Reject Alcon's Acquisition
Shareholders of STAAR Surgical are gearing up for a significant vote. Broadwood Partners, the company's largest shareholder with a 27.5% stake, has publicly opposed the proposed acquisition by Alcon. The virtual general assembly, set for October 23, 2025, will see this opposition led by Broadwood, supported by the former CEO David Bailey and another significant shareholder, Yunqi Capital Limited.
Broadwood Partners, along with its allies, has presented several arguments against the takeover. They contend that the timing of the acquisition is not favorable, suggesting that STAAR Surgical should focus on its own growth prospects rather than a sale. Additionally, they argue that the negotiation process has not been conducted in the best interests of STAAR's shareholders. The price offered by Alcon, they believe, does not fully reflect the value of STAAR Surgical.
David Bailey, the former CEO of STAAR, has lent his weight to Broadwood's campaign. With over four decades of leadership experience in the global healthcare and medical device industry, Bailey's opposition carries significant influence. Yunqi Capital Limited, holding a 5.1% stake in STAAR, has also joined the opposition, indicating a growing dissent among shareholders.
As the general assembly approaches, the opposition to the Alcon takeover is gaining momentum. Broadwood Partners, with the support of key figures like David Bailey and Yunqi Capital Limited, has presented a compelling case against the acquisition. The outcome of the vote will significantly shape the future of STAAR Surgical.
